REFERENCES
(1) Poster P29 from the Gene to Clinic meeting, December 2008. Sterry. W.
et al. Results of a Randomized, Double-Blind Study to Evaluate the
Efficacy and Safety of Etanercept in Patients with Psoriasis and
Psoriatic Arthritis: The PRESTA Trial
(2) Richards HL et al. The contribution of perceptions of stigmatization
to disability in patients with psoriasis. J Psychosom Res.
2001;50:11-15.
(3) Poster P30 from the Gene to Clinic meeting, December 2008. Barker, J.
et all. Improvement in the Dermatology Life Quality Index for
Patients With Psoriasis and Psoriatic Arthritis Treated with
Etanercept
For further information, please contact: Wyeth: Gill Markham, Communications - Europe, Middle East and Africa, Direct Tel: +44-1628-692536, Email: markhagl@wyeth.com; Danielle Halstrom, Communications - Global, Direct Tel: +1-484-865-2020, Email: halstrd@wyeth.com; OgilvyHealthPR: Mary Barrington-Ward, Tel: +44-207-108-6066, Email: mary.barrington-ward@ohpr.com; Nerea Hinzpeter, Tel: +1-212-625-4178, Email: Nerea.hinzpeter@ohpr.com
Andalucía
Aragón
Cantabria
Castilla-La Mancha
Castilla y León
Catalunya
Extremadura
Galicia
Islas Canarias
Islas Baleares
Madrid
País Vasco
La Rioja
C. Valenciana
Navarra
Asturias
Murcia
Ceuta y Melilla
